Posts by Sandra Ansanay-Alex
LICR, CHUV and UNIL extend their collaboration and renew their partnership
The Canton of Vaud, the Lausanne University Hospital (CHUV), the University of Lausanne (UNIL) and the Ludwig Institute for Cancer Research (LICR) have signed a new agreement. This agreement extends the presence of the Ludwig branch in Lausanne and strengthens their collaboration. This partnership has already attracted world-renowned scientists in the field of cancer. It…
Read MoreUCB Farchim Invests Over CHF 100 Million and Creates 80 New Jobs in Bulle
UCB Farchim, the Swiss subsidiary of Belgian biopharmaceutical group UCB, has announced a major new phase of development for its Bulle (Fribourg) site, with more than CHF 100 million in new investments and the creation of 80 additional jobs by 2030. Since opening in 1996, UCB has invested nearly CHF 700 million in its…
Read MoreHemostOD Secures CHF 4.3M Seed Extension
HemostOD, a Swiss Health Valley company pioneering the ex vivo manufacturing of donor-free, off-the-shelf universal human blood platelets, announces the successful closing of a CHF 4.3 million Seed-extension financing. The round was co-led by Polytech Ventures and Orenok Holdings, with additional participation from the Lichtsteiner Foundation and other private investors. Proceeds from this financing…
Read MoreAI-Powered Precision Oncology: NAIPO Launches in Switzerland
A new national initiative, NAIPO (National AI Initiative for Precision Oncology), is set to transform cancer care in Switzerland by leveraging artificial intelligence (AI) to enable truly personalized treatments. Led by the EPFL AI Center and ETH AI Center, NAIPO will run over four years and bring together a large, interdisciplinary team from Swiss…
Read MoreUndae Science and StudentsPool Supported by FIT
Two Swiss Health Valley startups supported by Fondation pour l’Innovation Technologique (FIT) are tackling some of healthcare’s most pressing challenges: diagnosing sleep disorders and addressing critical staff shortages. Undae Science: Making Sleep Monitoring Easier and More Accurate Sleep disorders affect one in three people in Switzerland and cost the economy more than CHF 10…
Read MoreGimv announces a CHF 28 Million Investment in Spineart
The European investment company listed on Euronext Brussels is thereby becoming a major shareholder. These funds will be used to strengthen Spineart’s organisation and commercial processes, pursue its geographical expansion in certain markets such as the United States, and continue the development of innovative products. Spineart is a rapidly growing Geneva-based medical device company.…
Read MoreBioArk & New Mexico Venture Studios Partner to Boost Life Sciences Projects
BioArk & New Mexico Venture Studios have established a strategic partnership to support startups in life sciences, medtech, and deep tech. This alliance facilitates access to infrastructure, expertise, and markets between US and European markets, accelerating international growth and collaboration. Facilitating startup expansion and collaboration The partnership provides startup exchange programs, shared lab and…
Read MoreBioLNP Innovation and OneCell Protein, recipients of the EPFL Startup Launchpad Ignition Grant
Two EPFL-based startups: BioLNP Innovation and OneCell Protein, have become the latest recipients of the EPFL Startup Launchpad Ignition grant. The startups were each awarded a CHF30,000 grant to continue developing their technology. BioLNP Innovation Viruses (including Respiratory Syncytial Virus or Hepatitis B) are a major public health concern. While scientists have developed treatments…
Read MoreARCHIMED acquires cell line development pioneer ExcellGene
Global private equity healthcare specialist ARCHIMED acquires a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting (both in the biologic therapeutics sector), partnering with founders and management, to create a group covering gene transfer, cell line development and cell culture-based manufacturing for high-performance production of recombinant proteins, and other advanced therapeutics. Monthey, Switzerland-based ExcellGene, was created…
Read MoreBioscibex Receives CHF 150,000 from Venture Kick
EPFL spin-off Bioscibex, a biotechnology start-up specialising in bioproduction equipment, has secured CHF 150,000 in funding from Venture Kick. This fundraising will accelerate the market launch of Swingo, its first single-use bioreactor, designed to simplify and automate cell culture and thus make biological therapies more accessible. Biologics have transformed the treatment of cancer, autoimmune…
Read More